Consensus statement on the use of rituximab in patients with rheumatoid arthritis
- 1 February 2007
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 143-150
- https://doi.org/10.1136/ard.2006.061002
Abstract
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.Keywords
This publication has 35 references indexed in Scilit:
- Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Patients' views on the quality of health care for rheumatoid arthritisRheumatology, 2006
- Tolerability and safety of rituximab (MabThera®)Cancer Treatment Reviews, 2005
- B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritisRheumatology, 2005
- Letter to the EditorLupus, 2004
- Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE projectQuality and Safety in Health Care, 2003
- Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximabAmerican Journal of Hematology, 2001
- Clinical outcome measures in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000